{"id":175129,"date":"2024-11-21T00:00:00","date_gmt":"2024-11-20T23:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/ciclosporine-risque-accru-de-fibroadenomes\/"},"modified":"2026-04-02T19:09:01","modified_gmt":"2026-04-02T17:09:01","slug":"ciclosporine-risque-accru-de-fibroadenomes","status":"publish","type":"post","link":"https:\/\/beta.bcfi.be\/fr\/ciclosporine-risque-accru-de-fibroadenomes\/","title":{"rendered":"Ciclosporine : risque accru de fibroad\u00e9nomes"},"content":{"rendered":"<p>Un article r&eacute;cent de <em>La Revue Prescrire<\/em> traite de 3 cas de fibroad&eacute;nomes du sein chez des femmes pr&eacute;m&eacute;nopaus&eacute;es prenant de la ciclosporine (Neoral&reg;). Les fibroad&eacute;nomes sont des tumeurs b&eacute;nignes fr&eacute;quentes&#x002C; principalement chez les femmes de moins de 35 ans. Des &eacute;tudes ant&eacute;rieures men&eacute;es chez des femmes ayant subi une transplantation r&eacute;nale ont d&eacute;j&agrave; montr&eacute; une association entre la ciclosporine et les fibroad&eacute;nomes. Le m&eacute;canisme exact n&#39;est pas encore enti&egrave;rement compris&#x002C; mais le d&eacute;veloppement des fibroad&eacute;nomes est probablement attribu&eacute; &agrave; des changements hormonaux ou &agrave; des effets sur les fibroblastes.<br \/> Il est important d&#39;informer les patients trait&eacute;s par ciclosporine de cet effet secondaire possible et de leur conseiller de consulter un m&eacute;decin en cas d&#39;apparition d&#39;une masse dans les seins. Actuellement&#x002C; les fibroad&eacute;nomes ne sont pas r&eacute;pertori&eacute;s comme un effet secondaire dans le RCP belge de la ciclosporine.<\/p>\n<h2> <strong>Sources<\/strong><\/h2>\n<p>Ciclosporine: fibroad&eacute;nomes du sein. <em>La Revue Prescrire<\/em> 2024&nbsp;;44&nbsp;:666 (n&deg;491&#x002C; septembre 2024)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un article r&eacute;cent de La Revue Prescrire traite de 3  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,20295],"tags":[20213,20224],"class_list":["post-175129","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2024-fr","tag-import_tags","tag-import_tags-nl"],"_links":{"self":[{"href":"https:\/\/beta.bcfi.be\/fr\/wp-json\/wp\/v2\/posts\/175129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beta.bcfi.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/beta.bcfi.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/beta.bcfi.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/beta.bcfi.be\/fr\/wp-json\/wp\/v2\/comments?post=175129"}],"version-history":[{"count":1,"href":"https:\/\/beta.bcfi.be\/fr\/wp-json\/wp\/v2\/posts\/175129\/revisions"}],"predecessor-version":[{"id":177711,"href":"https:\/\/beta.bcfi.be\/fr\/wp-json\/wp\/v2\/posts\/175129\/revisions\/177711"}],"wp:attachment":[{"href":"https:\/\/beta.bcfi.be\/fr\/wp-json\/wp\/v2\/media?parent=175129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/beta.bcfi.be\/fr\/wp-json\/wp\/v2\/categories?post=175129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/beta.bcfi.be\/fr\/wp-json\/wp\/v2\/tags?post=175129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}